Publication | Open Access

Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial

OncologyClinical TrialsColorectal CancerPathologyUpfront FolfoxiriMetastatic Colorectal CancerPharmacotherapyCancer TreatmentPhase 2MedicineRadiation OncologyHealth Sciences